The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - Shockwave Medical
Consulting or Advisory Role - AstraZeneca; Kite, a Gilead Company; Sanofi
Speakers' Bureau - Bristol-Myers Squibb
Efficacy and safety of LY3537982, a potent and highly selective KRAS G12C inhibitor in KRAS G12C-mutant GI cancers: Results from a phase 1 study.
 
Antoine Hollebecque
Honoraria - Amgen; Eisai; Incyte; Relay Therapeutics; SERVIER
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune (Inst); Debiopharm Group (Inst); Gritstone Bio; Incyte (Inst); Lilly (Inst); QED therapeutics; Relay Therapeutics; Spectrum Pharmaceuticals (Inst); Taiho Oncology
Research Funding - AstraZeneca/MedImmune (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Incyte; Lilly; Roche; SERVIER
Other Relationship - Abbvie; Agios; Amgen; argenx; Arno Therapeutics; Astex Pharmaceuticals; AstraZeneca; AVEO; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Debiopharm Group; Eisai; Exelixis; FORMA Therapeutics; GamaMabs Pharma; Genentech; GlaxoSmithKline; H3 Biomedicine; Innate Pharma; Janssen-Cilag; Kyowa Hakko Kirin; Lilly; Loxo; Lytix Biopharma; MedImmune; Menarini; Merck Sharp & Dohme; Merrimack; Merus; Millenium Pharamceuticals; Nanobiotix; Nektar; Novartis; Octimet; Oncoethix; Onyx; Orion; Oryzon Genomics; Pfizer; Pierre Fabre; Roche; Roche/Genentech; Sanofi/Aventis; SERVIER; Taiho Pharmaceutical; Tesaro; Xencor
 
Yasutoshi Kuboki
Honoraria - Bristol-Myers Squibb Japan; Lilly Japan; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Incyte; Janssen Oncology; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Oncology (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Lilly (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; Incyte
 
Yonina R. Murciano-Goroff
Employment - Memorial Sloan-Kettering Cancer Center
Honoraria - Amgen; Virology Education
Research Funding - Andrew Sabin Family Foundation; Conquer Cancer, the ASCO Foundation; Conquer Cancer, the ASCO Foundation; Druckenmiller Center for Lung Cancer Research; Elucida Oncology (Inst); Endeavor BioMedicines (Inst); Hengrui Pharmaceutical (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Loxo Oncology / Eli Lilly (Inst); Loxo Oncology / Eli Lilly (Inst); Loxo/Lilly (Inst); Luzsana Biotechnology (Inst); Mirati Therapeutics (Inst); National Cancer Institute; National Cancer Institute; Taiho Oncology (Inst); The Society of Memorial Sloan Kettering
Patents, Royalties, Other Intellectual Property - Rutgers University Press; Wolters Kluwer
Travel, Accommodations, Expenses - AstraZeneca; Loxo Oncology/ Eli Lilly
Other Relationship - Endeavor Biomedicines
 
Rona Yaeger
Honoraria - Zai Lab
Consulting or Advisory Role - Mirati Therapeutics
Research Funding - Boehringer Ingelheim (Inst); Daiichi Sankyo/UCB Japan (Inst); Daiichi Sankyo/UCB Japan (Inst); Mirati Therapeutics (Inst); Pfizer (Inst)
 
Philippe Alexandre Cassier
Honoraria - Amgen
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb/Celgene; Janssen Oncology; OSE Immunotherapeutics
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Innate Pharma (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst); Transgene (Inst)
Travel, Accommodations, Expenses - Novartis; OSE Immunotherapeutics; Roche
 
Rebecca Suk Heist
Consulting or Advisory Role - Abbvie; AstraZeneca; Claim Therapeutics; Daichii Sankyo; Daichii Sankyo; Lilly; Novartis; Regeneron; Sanofi
Research Funding - Abbvie (Inst); Agios (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Exelixis (Inst); Exelixis (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Mythic Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche (Inst); Turning Point Therapeutics (Inst)
 
Yutaka Fujiwara
Honoraria - Amgen; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly Japan; Merck; MSD; Nihonkayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chiome Bioscience; Daiichi Sankyo; MSD; Ono Pharmaceutical; Otsuka
Research Funding - Abbvie (Inst); Amgen (Inst); Anheart Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Incyte (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst)
 
Dustin A. Deming
Consulting or Advisory Role - Bayer; Lilly; Pfizer; Seagen
Research Funding - AADi (Inst); Arcus Ventures (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Curegenix (Inst); Genentech (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Natera (Inst); Promega (Inst); Revolution Medicines (Inst); Strata Oncology (Inst)
 
Natraj Ammakkanavar
No Relationships to Disclose
 
Amita Patnaik
Honoraria - Texas Society of Clinical Oncology (TxSCO)
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb (I); Daiichi Sankyo, Inc.; Genentech/Roche (I); Gilead Sciences; HalioDx; Ionova; Janssen; Merck; MERCK (I); Novartis; Seagen; Silverback Therapeutics
Research Funding - 1200 Pharma (Inst); AADi (Inst); Abbvie (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arcus Ventures (Inst); Astellas Pharma (Inst); Bolt Biotherapeutics (Inst); Carrick Therapeutics (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi-Sankyo (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fochon Pharmaceuticals (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Institut de Recherches Internationales Servier (I.R.I.S) (Inst); Ionova (Inst); Ionova (Inst); Klus Pharma (Inst); KSQ Therapeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo@Lilly (Inst); Merck (Inst); Nektar (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Prelude Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Surface Oncology (Inst); Symphogen (Inst); Syndax (Inst); Tesaro (Inst); Upsher-Smith (Inst); Vigeo Therapeutics (Inst)
 
Toshio Shimizu
Honoraria - Chugai Pharma; Daiichi Sankyo; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; Chordia Therapeutics; Daiichi Sankyo; Takeda
Speakers' Bureau - Chugai Pharma
Research Funding - 3D Medicines (Inst); Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chordia Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Incyte (Inst); Lilly (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); SymBio Pharmaceuticals (Inst); Takeda/Millennium (Inst)
Travel, Accommodations, Expenses - Takeda
 
Justin Call
No Relationships to Disclose
 
Sae-Won Han
Honoraria - IMBdx
Research Funding - Arcus Biosciences (Inst); BeyondBio (Inst); GC Pharma (Inst); Genentech (Inst); Hanmi (Inst); Hengrui Pharmaceutical (Inst); IMBdx (Inst); Janssen (Inst); Jeil Pharmaceutical Co (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Mirati Therapeutics (Inst); MSD (Inst); Roche (Inst); Seagen (Inst); Turnstone Bio (Inst)
 
Aaron Alan Fink
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Travel, Accommodations, Expenses - Lilly
 
Aaron Chen
Employment - Loxo/Lilly; Sumitomo Pharma Oncology
Stock and Other Ownership Interests - Loxo/Lilly
Travel, Accommodations, Expenses - Loxo/Lilly
 
Melinda D Willard
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Travel, Accommodations, Expenses - Lilly
 
Arjun Vasant Balar
Employment - Loxo/Lilly
Stock and Other Ownership Interests - Lilly
Honoraria - AstraZeneca/MedImmune; Genentech/Roche; Merck
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb/Celgene; Cerulean Pharma; Dragonfly Therapeutics; Genentech/Roche; GlaxoSmithKline; Incyte; Merck; Nektar; Pfizer/EMD Serono; Seattle Genetics/Astellas
Research Funding - AstraZeneca/MedImmune (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Merck (Inst); Seagen
 
Takafumi Koyama
Honoraria - Chugai Pharma; Sysmex
Consulting or Advisory Role - Amgen
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo RD Novare (Inst); Lilly (Inst); Novartis (Inst); PACT Pharma (Inst); Pfizer (Inst); Takeda (Inst); Zymeworks (Inst)